AstraZeneca’s Imjudo (tremelimumab) + Imfinzi (durvalumab) Receive the US FDA’s Approval for Unresectable Liver Cancer
Shots:
- The approval was based on the P-III (HIMALAYA) trial evaluating Imjudo (300mg) + Imfinzi (1500mg, q4w) vs sorafenib in 1324 patients with HCC prior not treated with systemic therapy & not eligible for LRT at 181 centers across 16 countries
- The results showed that patients treated with the combination experienced a 22% reduction in risk of death, 31% vs 20% were still alive after 3yrs. vs the same duration of follow-up. The results were published in the NEJM with no increase in severe liver toxicity or bleeding risk
- The safety profiles were consistent with the known therapy profiles with no new safety signals. The regulatory applications are currently under review in the EU, Japan & multiple other countries for advanced liver cancer
Ref: AstraZeneca | Image: AstraZeneca’
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
